Treatment Variation in Older Adults With Differentiated Thyroid Cancer

被引:4
|
作者
Sutton, Whitney [1 ]
Canner, Joseph K. [1 ]
Segev, Dorry L. [1 ]
Zeiger, Martha A. [2 ]
Mathur, Aarti [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, 600 North Wolfe St,Blalock 606, Baltimore, MD 21287 USA
[2] NCI, Dept Surg Oncol, NIH, Bethesda, MD 20892 USA
关键词
Thyroid cancer; Aging; Thyroidectomy; Disease-specific mortality; ASSOCIATION MANAGEMENT GUIDELINES; UNITED-STATES; YOUNG AGE; PAPILLARY; SURVIVAL; PREDICTORS; PROGNOSIS; MORTALITY; NODULES; PATIENT;
D O I
10.1016/j.jss.2020.04.013
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The growth of the aging population coupled with the increasing incidence of thyroid cancer warrants a better understanding of thyroid cancer in older adults. We aimed to investigate the variation of treatment patterns and determine if the extent of surgery is associated with disease-specific mortality in older adults with differentiated thyroid cancer (DTC). Methods: We performed a population-based study using the Surveillance, Epidemiology, and End Results 18 program to examine patients diagnosed with DTC between 2004 and 2015. Patients were stratified by age: younger adults (aged 18-54 y), middle adults (aged 5564 y), older adults (aged 65-79 y), and super elderly (aged >= 80 y). Disease-specific mortality was estimated using Kaplan-Meier curves and compared using the log-rank test. Multi variable Cox regression was used to assess associations between clinicopathologic characteristics and treatment patterns on disease-specific mortality. Results: Of 117,098 patients with DTC, 72,368 were younger adults, 23,726 middle adults, 18,119 older adults, and 2885 were super elderly. In patients with DTC, compared with younger adults, fewer middle, older, and super elderly adults underwent any surgery (99.0%, 98.4%, 97.4%, and 89.1%, respectively; P < 0.001) or received radioactive iodine (RAI; 48.7%, 42.5%, 39.7%, and 30.7%, respectively; P < 0.001). Furthermore, middle, older, and super elderly adults had higher risk of mortality from DTC (hazard ratio [HR]: 4.0, 95% confidence interval [CI]: 3.2-4.8, P < 0.001; HR: 7.6, 95% CI: 6.3-9.1, P < 0.001; and HR: 17.2, 95% CI: 13.8-21.3, P < 0.001, respectively). On multivariable Cox regression while adjusting for clinicopathologic confounders, management was a significant prognostic factor (no surgery HR: 3.8, 95% CI: 3.1-4.6, P < 0.001; and RAI HR: 0.7, 95% CI: 0.6-0.8, P < 0.001). Conclusions: In patients with DTC, fewer older adults (>= 65 y) underwent surgery or treatment with RAI, and this was associated with a worse disease-specific survival. Surgical decision-making in the older population is complex, and future prospective studies are needed to assess this age-related treatment variation. (c) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:154 / 164
页数:11
相关论文
共 50 条
  • [31] Patient disability and treatment variation among older adults with kidney cancer.
    Tan, Hung-Jui
    Chamie, Karim
    Litwin, Mark S.
    Hu, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [32] Treatment strategy by radioiodine refractory differentiated thyroid cancer
    Mantsopoulos, Konstantinos
    Mueller, Sarina K.
    Pavel, Marianne
    Kuwert, Torsten
    Meidenbauer, Norbert
    Fietkau, Rainer
    Sievert, Matti
    Iro, Heinrich
    LARYNGO-RHINO-OTOLOGIE, 2022, 101 (04) : 298 - 303
  • [33] Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
    Kreissl, Michael C.
    Janssen, Marcel J. R.
    Nagarajah, James
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (01) : 9 - 15
  • [34] UPDATE ON THE DIAGNOSIS AND TREATMENT OF DIFFERENTIATED THYROID CANCER Foreword
    Bombardieri, Emilio
    Pacini, Furio
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 53 (05): : 439 - 439
  • [35] Local treatment of metastases from differentiated thyroid cancer
    Bonichon, F.
    Buy, X.
    Godbert, Y.
    Pointillart, V.
    de Figueiredo, B. Henriques
    Gangi, A.
    Palussiere, J.
    ANNALES D ENDOCRINOLOGIE, 2015, 76 : 1S40 - 1S46
  • [36] Radioiodine treatment of well-differentiated thyroid cancer
    Leonard Wartofsky
    Douglas Van Nostrand
    Endocrine, 2012, 42 : 506 - 513
  • [37] Oxidative stress and radioiodine treatment of differentiated thyroid cancer
    Buczynska, Angelika
    Sidorkiewicz, Iwona
    Rogucki, Mariusz
    Siewko, Katarzyna
    Adamska, Agnieszka
    Kosciuszko, Maria
    Maliszewska, Katarzyna
    Kozlowska, Gabryela
    Szumowski, Piotr
    Mysliwiec, Janusz
    Dzieciol, Janusz
    Kretowski, Adam
    Poplawska-Kita, Anna
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [38] Risk management of radioiodine treatment in differentiated thyroid cancer
    Villena-Salinas, J.
    Alcocer, M. A. Sempere
    Peinado, M. Gallego
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2024, 43 (04):
  • [39] Recurrent Differentiated Thyroid Cancer: The Current Treatment Options
    Coca-Pelaz, Andres
    Rodrigo, Juan Pablo
    Shah, Jatin P.
    Nixon, Iain J.
    Hartl, Dana M.
    Robbins, K. Thomas
    Kowalski, Luiz P.
    Makitie, Antti A.
    Hamoir, Marc
    Lopez, Fernando
    Saba, Nabil F.
    Nuyts, Sandra
    Rinaldo, Alessandra
    Ferlito, Alfio
    CANCERS, 2023, 15 (10)
  • [40] Differentiated Thyroid Cancer-Treatment: State of the Art
    Schmidbauer, Benedikt
    Menhart, Karin
    Hellwig, Dirk
    Grosse, Jirka
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (06)